Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 8/20 | 0.54 |
| ▸ | HTR7 | P34969 | 6/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.52 |
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | HTR6 | P50406 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839759 | 1.00 | OPRM1 (0.54) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL7214486 | 0.85 | OPRM1 (0.56) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL7214372 | 0.81 | ADRA1D (0.58) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL4835916 | 0.79 | ADRA1D (0.54) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL4833089 | 0.79 | HSD11B1 (0.55) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL5396886 | 0.78 | ADRA1D (0.82) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL4838880 | 0.77 | ADRA1D (0.52) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL4833023 | 0.77 | HTR1D (0.54) | ADRA1DADRA1BHTR1AHTR7SLC6A4 | |
| SCHEMBL4830099 | 0.77 | ADRA1D (0.51) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL7529023 | 0.77 | HTR1A (0.64) | OPRM1OPRK1OPRL1HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | KCNJ2, KCNK2, KCNJ11 | OPRM1 1618/4885OPRK1 271/4885OPRL1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.